Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms

(2018) Maria Kleppe et al.   CANCER CELL

Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion

(2018) William L. Heaton et al.   LEUKEMIA

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance

(2018) Dilana Staudt et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium

(2017) Martin Griesshammer et al.   EXPERT OPINION ON PHARMACOTHERAPY

Mass cytometry identifies a distinct monocyte cytokine signature shared by clinically heterogeneous pediatric SLE patients

(2017) W.E. O'Gorman et al.   JOURNAL OF AUTOIMMUNITY

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

(2017) Srdan Verstovsek et al.   Journal of Hematology & Oncology

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

(2017) Srdan Verstovsek et al.   Journal of Hematology & Oncology

Does ruxolitinib prolong the survival of patients with myelofibrosis?

(2016) Francisco Cervantes et al.   BLOOD

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms

(2016) William Vainchenker et al.   BLOOD

Monoclonal antibody 1.6.1 against human MPL receptor allows HSC enrichment of CB and BM CD34+CD38− populations

(2016) Laurence Petit Cocault et al.   EXPERIMENTAL HEMATOLOGY

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

(2016) Vikas Gupta et al.   HAEMATOLOGICA

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

(2016) John O. Mascarenhas et al.   HAEMATOLOGICA

Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia

(2016) D A C Fisher et al.   LEUKEMIA

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation

(2016) S. Elf et al.   Cancer Discovery

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

(2016) Vikas Gupta et al.   HAEMATOLOGICA

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

(2016) John O. Mascarenhas et al.   HAEMATOLOGICA

Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation

(2016) S. Yang et al.   Cancer Immunology Research

The Role of Toll-Like Receptors in Hematopoietic Malignancies

(2016) Darlene A. Monlish et al.   Frontiers in Immunology

IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells

(2015) C. Schinke et al.   BLOOD

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis

(2015) M. Deininger et al.   BLOOD

Clinical and molecular genetic characterization of myelofibrosis

(2015) Gabriela S. Hobbs et al.   CURRENT OPINION IN HEMATOLOGY

Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia

(2015) J Khalife et al.   LEUKEMIA

Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm

(2015) Eli R Zunder et al.   Nature Protocols

JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

(2015) M. Kleppe et al.   Cancer Discovery

Prognostication in MF: From CBC to cytogenetics to molecular markers

(2014) Amy Zhou et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis

(2014) R. Norfo et al.   BLOOD

Preclinical efficacy of MEK inhibition in Nras-mutant AML

(2014) M. R. Burgess et al.   BLOOD

Physiological functions of TNF family receptor/ligand interactions in hematopoiesis and transplantation

(2014) K. Mizrahi et al.   BLOOD

Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity

(2014) Yuki Kagoya et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth

(2014) Thanh U. Barbie et al.   JOURNAL OF CLINICAL INVESTIGATION

Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML

(2014) Andrew Volk et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

(2014) A Tefferi et al.   LEUKEMIA

Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit

(2014) Z. Zhu et al.   Cancer Discovery

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

(2013) A Pardanani et al.   LEUKEMIA

Toll-like receptor alterations in myelodysplastic syndrome

(2013) Y Wei et al.   LEUKEMIA

viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia

(2013) El-ad David Amir et al.   NATURE BIOTECHNOLOGY

MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice

(2013) Jimmy L Zhao et al.   eLife

Discovery of Potent and Selective Covalent Inhibitors of JNK

(2012) Tinghu Zhang et al.   CHEMISTRY & BIOLOGY

TNF  facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms

(2011) A. G. Fleischman et al.   BLOOD

Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets

(2011) K. L. Wong et al.   BLOOD

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors

(2011) Cornelis J.H. Pronk et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE

(2011) Peng Qiu et al.   NATURE BIOTECHNOLOGY

Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum

(2011) S. C. Bendall et al.   SCIENCE

The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor

(2011) John P. Duffy et al.   ACS Medicinal Chemistry Letters

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms

(2010) S. T. Oh et al.   BLOOD

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia

(2010) R. T. Swords et al.   BLOOD

Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling

(2010) Edwin Chen et al.   CANCER CELL

Highly multiparametric analysis by mass cytometry

(2010) Olga Ornatsky et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA

Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

(2008) Jennifer Grosjean-Raillard et al.   APOPTOSIS

ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

(2008) J Grosjean-Raillard et al.   ONCOGENE